Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3937441rdf:typepubmed:Citationlld:pubmed
pubmed-article:3937441lifeskim:mentionsumls-concept:C0029921lld:lifeskim
pubmed-article:3937441lifeskim:mentionsumls-concept:C0085228lld:lifeskim
pubmed-article:3937441lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:3937441pubmed:issue5lld:pubmed
pubmed-article:3937441pubmed:dateCreated1986-2-24lld:pubmed
pubmed-article:3937441pubmed:abstractTextFluvoxamine, a new antidepressant that specifically inhibits serotonin reuptake, was studied in 272 outpatients in a six-week multicentre trial in Belgium. On the Hamilton Depression Scale, the mean score dropped from 25.2 to 8 after six weeks (p less than 0.00001). The Clinical Global Impression scores showed similar evolution. Fluvoxamine is a real antidepressant with a marked effect on mood. Its effective dosage is 100 mg to 200 mg/day. Its tolerance, notably at the cardiovascular level, is excellent.lld:pubmed
pubmed-article:3937441pubmed:languageenglld:pubmed
pubmed-article:3937441pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3937441pubmed:citationSubsetIMlld:pubmed
pubmed-article:3937441pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3937441pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3937441pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3937441pubmed:statusMEDLINElld:pubmed
pubmed-article:3937441pubmed:issn0300-8967lld:pubmed
pubmed-article:3937441pubmed:authorpubmed-author:UytdenhoefPPlld:pubmed
pubmed-article:3937441pubmed:authorpubmed-author:BrasseurRRlld:pubmed
pubmed-article:3937441pubmed:authorpubmed-author:Van...lld:pubmed
pubmed-article:3937441pubmed:authorpubmed-author:AnsseauMMlld:pubmed
pubmed-article:3937441pubmed:authorpubmed-author:MesottenFFlld:pubmed
pubmed-article:3937441pubmed:authorpubmed-author:BartholomeFFlld:pubmed
pubmed-article:3937441pubmed:issnTypePrintlld:pubmed
pubmed-article:3937441pubmed:volume85lld:pubmed
pubmed-article:3937441pubmed:ownerNLMlld:pubmed
pubmed-article:3937441pubmed:authorsCompleteYlld:pubmed
pubmed-article:3937441pubmed:pagination636-43lld:pubmed
pubmed-article:3937441pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:3937441pubmed:meshHeadingpubmed-meshheading:3937441-...lld:pubmed
pubmed-article:3937441pubmed:meshHeadingpubmed-meshheading:3937441-...lld:pubmed
pubmed-article:3937441pubmed:meshHeadingpubmed-meshheading:3937441-...lld:pubmed
pubmed-article:3937441pubmed:meshHeadingpubmed-meshheading:3937441-...lld:pubmed
pubmed-article:3937441pubmed:meshHeadingpubmed-meshheading:3937441-...lld:pubmed
pubmed-article:3937441pubmed:meshHeadingpubmed-meshheading:3937441-...lld:pubmed
pubmed-article:3937441pubmed:meshHeadingpubmed-meshheading:3937441-...lld:pubmed
pubmed-article:3937441pubmed:meshHeadingpubmed-meshheading:3937441-...lld:pubmed
pubmed-article:3937441pubmed:meshHeadingpubmed-meshheading:3937441-...lld:pubmed
pubmed-article:3937441pubmed:meshHeadingpubmed-meshheading:3937441-...lld:pubmed
pubmed-article:3937441pubmed:articleTitleA Belgian multicentre study of fluvoxamine in depressive outpatients.lld:pubmed
pubmed-article:3937441pubmed:publicationTypeJournal Articlelld:pubmed